Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies

Código QR

Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies

Abstract To find metastatic recurrence biomarkers of triple-negative breast cancer (TNBC) treated by neoadjuvant chemotherapy and anti-EGFR antibodies (NAT), we evaluated tumor genomic, transcriptomic, and immune features, using MSK-IMPACT assay, gene arrays, Nanostring technology, and TIL assessmen...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nina Radosevic-Robin, Pier Selenica, Yingjie Zhu, Helen H. Won, Michael F. Berger, Lorenzo Ferrando, Emiliano Cocco, Maud Privat, Flora Ponelle-Chachuat, Catherine Abrial, Jean-Marc Nabholtz, Frederique Penault-Llorca, Jorge S. Reis-Filho, Maurizio Scaltriti
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/5085bbfc4563442588c40da205b8c222
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Triple-Negative Breast Cancer: Assessing the Role of Immunohistochemical Biomarkers on Neoadjuvant Treatment
por: da Silva JL, et al.
Publicado: (2021)

Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy
por: Maria Vittoria Dieci, et al.
Publicado: (2021)

Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
por: Julia Foldi, et al.
Publicado: (2021)

Targeting mTOR and DNA repair pathways in residual triple negative breast cancer post neoadjuvant chemotherapy
por: Kartik Anand, et al.
Publicado: (2021)

Prognostic Influence of Residual Tumor-Infiltrating Lymphocyte Subtype After Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
por: Jesse Lopes da Silva, et al.
Publicado: (2021)

A Combined Nomogram Model to Predict Disease-free Survival in Triple-Negative Breast Cancer Patients With Neoadjuvant Chemotherapy
por: Bingqing Xia, et al.
Publicado: (2021)

Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Pairwise and Network Meta-Analysis of Pathological Complete Response
por: Zeng-Jie Weng MM, et al.
Publicado: (2021)

Regulation of low-density lipoprotein receptor expression in triple negative breast cancer by EGFR-MAPK signaling
por: Tiffany Scully, et al.
Publicado: (2021)

Deguelin action involves c-Met and EGFR signaling pathways in triple negative breast cancer cells.
por: Rajeshwari Mehta, et al.
Publicado: (2013)

Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triple-negative breast cancer: a systematic review and meta-analysis
por: Yuanfang Xin, et al.
Publicado: (2021)

Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy
por: Yu-Hsiang Chen, et al.
Publicado: (2017)

Efficacy and Safety of Adding Immune Checkpoint Inhibitors to Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials
por: Yunhai Li, et al.
Publicado: (2021)

The Epigenetic Landscape of Promoter Genome-wide Analysis in Breast Cancer
por: Seher Karsli-Ceppioglu, et al.
Publicado: (2017)

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
por: Wen M, et al.
Publicado: (2018)

Identification of a new regulation pathway of EGFR and E-cadherin dynamics
por: Veronique Proux-Gillardeaux, et al.
Publicado: (2021)

Including total EGFR staining in scoring improves EGFR mutations detection by mutation-specific antibodies and EGFR TKIs response prediction.
por: Shang-Gin Wu, et al.
Publicado: (2011)

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
por: Beth O. Van Emburgh, et al.
Publicado: (2016)

Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity
por: Takahiro Yoshizawa, et al.
Publicado: (2021)

Effect of Epigallocatechin-3-Gallate on EGFR Signaling and Migration in Non-Small Cell Lung Cancer
por: Cristina Minnelli, et al.
Publicado: (2021)

Temporal determinants of tumour response to neoadjuvant rectal radiotherapy.
por: Kendrick Koo, et al.
Publicado: (2021)

Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma
por: Willard Wong, et al.
Publicado: (2021)

Inhibition of Vasculogenic Mimicry and Angiogenesis by an Anti-EGFR IgG1-Human Endostatin-P125A Fusion Protein Reduces Triple Negative Breast Cancer Metastases
por: Seung-Uon Shin, et al.
Publicado: (2021)

Approaching Neoadjuvant Therapy in the Management of Early-Stage Breast Cancer
por: Hyder T, et al.
Publicado: (2021)

Genetic variant rs10251977 (G>A) in EGFR-AS1 modulates the expression of EGFR isoforms A and D
por: Shankar Dhamodharan, et al.
Publicado: (2021)

Anti-EGFR antibody 528 binds to domain III of EGFR at a site shifted from the cetuximab epitope
por: Koki Makabe, et al.
Publicado: (2021)

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
por: Rajeswara Rao Arasada, et al.
Publicado: (2018)

Impact of EGFR mutation detection methods on the efficacy of erlotinib in patients with advanced EGFR-wild type lung adenocarcinoma.
por: Jeng-Sen Tseng, et al.
Publicado: (2014)

Quantification and kinetic analysis of Grb2-EGFR interaction on micro-patterned surfaces for the characterization of EGFR-modulating substances.
por: Peter Lanzerstorfer, et al.
Publicado: (2014)

Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
por: Ken Uchibori, et al.
Publicado: (2017)

Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors
por: Jana Fassunke, et al.
Publicado: (2018)

Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines.
por: Jeet Gandhi, et al.
Publicado: (2009)

Neoadjuvant immunotherapy for resectable esophageal cancer: A protocol of meta-analysis.
por: Guocan Yu, et al.
Publicado: (2021)

Neoadjuvant chemotherapy for advanced stage endometrial cancer: A systematic review
por: Allan B. Huang, et al.
Publicado: (2021)

Neoadjuvant immune checkpoint inhibitor plus chemotherapy in rare tracheal tumors
por: Ben‐Yuan Jiang, et al.
Publicado: (2021)

Quantitative multiparametric MRI predicts response to neoadjuvant therapy in the community setting
por: John Virostko, et al.
Publicado: (2021)

Current neoadjuvant treatment options for HER2 positive breast cancer
por: Abdel-Razeq H, et al.
Publicado: (2011)

A Study on Clinical and Pathological Responses to Neoadjuvant Chemotherapy in Breast Carcinoma
por: Kunnuru SKR, et al.
Publicado: (2020)

EGFR soluble isoforms and their transcripts are expressed in meningiomas.
por: Angélique Guillaudeau, et al.
Publicado: (2012)

Inhibition of EGFR Signaling Protects from Mucormycosis
por: Tonya N. Watkins, et al.
Publicado: (2018)

EGFRAP encodes a new negative regulator of the EGFR acting in both normal and oncogenic EGFR/Ras-driven tissue morphogenesis.
por: Jennifer Soler Beatty, et al.
Publicado: (2021)